BIOSYNEX |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.09 EUR | -0.73% |
|
-19.80% | -51.02% |
| 2023 | Biosynex: merger with Theradiag completed | CF |
| 2023 | Biosynex SA Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Biosynex specializes in the research, development and manufacturing of fast diagnosis tests on membrane support for health professionals (biologists, clinicians, nurses and midwives). Products are used in the tropical diseases, autoimmune diseases, emergency markers and Infectious diseases fields. The company's activity is organized around 5 areas:
- manufacturing of diagnosis tests for own account;
- sale of diagnosis tests supplied by other manufacturers of semi-finished products;
- research and development services for third party;
- sale of licenses;
- sale of biological reagents.
At the end of 2022, the group had one production site located in France.
France accounts for 61.1% of net sales.
| 1st Jan change | Capi. | |
|---|---|---|
| -51.02% | 46.99M | |
| +0.89% | 12.8B | |
| -10.29% | 7.61B | |
| +1.78% | 5.41B | |
| -1.16% | 4.51B | |
| +5.74% | 4.49B | |
| -50.70% | 3.29B | |
| +12.21% | 2.73B | |
| -16.13% | 2.02B | |
| -11.50% | 1.73B |
- Stock Market
- Equities
- ALBIO Stock
- News Biosynex
- Biosynex Unit to Acquire US-based Biotech Qualigen
